Table 1.
Seroreactivity to recombinant Plasmodium falciparum apical membrane antigen 1 and merozoite surface protein 1 C-terminal 19-kD variants by protein microarray*
| Antigen | Cohort | Mean MFI (95% CI) | Serorecognition (%, 95% CI) | ||
|---|---|---|---|---|---|
| Pre-season | Post-season | Pre-season | Post-season | ||
| AMA1 | Children | 296 (226–365) | 434 (348–522) | 13.1 (5.8–20.4) | 18.6 (11.1– 26.1) |
| Adults | 1,506 (1,324–1,687) | 1,428 (1,271–1,585) | 49.3 (37.0–61.6) | 53.2 (42.7–63.7) | |
| Controls | 8.78 (5.22–12.4) | – | – | – | |
| MSP119 | Children | 20.9 (4.40–37.5) | 191 (110–273) | 2.5 (–0.9 to 5.9) | 9.4 (3.5–15.4) |
| Adults | 627 (345–909) | 940 (474–1,406) | 21.1 (11.4–30.9) | 18.9 (6.3–31.4) | |
| Controls | 21.4 (16.8–26.05) | – | – | – | |
*
Serum samples from Malian children and adult were considered positive for a given antigen variant if the mean MFI was 2 SD above the average of 30 malaria-naive North American controls. Serorecognition is given as the average percentage of AMA1 and MSP119 variants recognized by each cohort at each time point.
MFI = median fluorescence intensity; CI = confidence interval; AMA1 = apical membrane antigen 1; MSP119 = merozoite surface protein 1 C-terminal 19 kD.